In addition, we continue to encourage producers and States to cooperate to ensure that appropriate payments are made and that credits are used in a timely manner. (f) The rebate agreement must be interpreted in accordance with federal law and ambiguities must be interpreted in the manner most consistent with the legal construction. Compliance Date: The publication of CMS-2397-FN serves as a written communication on a good reason to terminate all existing discount agreements from the first day of the full calendar quarter, which will begin at least 6 months after the effective date of the updated NDRA (October 1, 2018). Manufacturers with an existing Active Start-up Printed Page 12771NDRA have at least 2 full calendar quarters to sign and submit the updated NDRA as of the effective date of this release. We will soon be publishing more guidelines on this subject. (j) to continue to pay a discount on all of its covered ambulatory drugs as long as an agreement with the Secretary is in effect and the State`s usage data indicates that payment has been made for that drug, whether or not the manufacturer continues to market that drug. . . .